Advertisement

Picture Berlin Partner Top News Captain T Cell Therapies 650x100px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 3488 | Ordered by Date (descending)
next pagenext page 1 2 3 ... 23 24 25 ... 33 34 35  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Spindiag–WBG Pflegeheime: investment, 202005 financing round Series B totalling €16.3m incl existing investor WBG Pflegeheime 2020-05-26
Sterna Biologicals–MC Services: public relations, 202005 service existent by MC Services 2020-05-26
Sterna Biologicals–SEVERAL: investment, 202005 financing round Series A first closing €12m with existing + new investors 2020-05-26
Themis Bioscience–Merck (US): investment, 202005– acquisition €na all remaing shares of Themis via Merck subsidiary 2020-05-26
Poxel–Trophic Communications: public relations, 202005 service existent IR+ media EU/US by Trophic Communications 2020-05-25
Stratos–Roche: investment, 202005 acquisition €na of Stratos Genomics by Roche 2020-05-22
Idorsia–SEVERAL: investment, 202005 capital increase CHF330m offering of 11m new shares at CHF30/share to qualified investors 2020-05-19
Rentschler–Horizon Discovery: cell line development, 202005– license to CHOSource platform for cell line developm for difficult-to-express proteins 2020-05-19
Rentschler–MC Services: public relations, 202005 service existent by MC Services 2020-05-19
Roche–Vividion Therapeutics: drug discovery, 202005– collab ww excl option + license agreem $135m upfront small molecules targeting E3 ligases 2020-05-19
Apeiron–Austria (govt): grant, 202005– grant funding + guarantees €5.6m from FFG + WAW + AWS + Erste Bank 2020-05-18
Apeiron–SEVERAL: investment, 202005–202006 private placement €11.9m led by Vienna Insurance Group plus existing + new investors 2020-05-18
Apeiron–Vienna Insurance Group: investment, 202005–202006 private placement totalling €11.9m incl €7m from new + lead investor VIG 2020-05-18
Enzymicals–Syngulon: enzyme production technology, 202005– license non-excl to antibiotic-free selection technology of Syngulon 2020-05-16
OTHER–Enzymicals: enzymes, 202005 service production + supply of diagnostic enzymes using antibiotic-free production for undisclosed world leader 2020-05-16
Ori Biotech–CellGenix: reagents, 202005– collab supply of GMP raw materials for closed-system CGT manufacturing system of Ori 2020-05-13
Polyganics–EU (govt): grant, 202005 EFRO grant €1.2m for clinical development of Liver + Pancreas Sealant Patch 2020-05-13
Bluebird Bio–Showa Denko: contract manufacturing, 202005– supply expansion long-term developm + manufacturing by HCATS + Apceth for gene therapies 2020-05-11
Novartis–Dyno Therapeutics: gene therapy, 202005– collab design of AVV vectors for ophthalmic gene therapies using AI-based CapsidMap platform 2020-05-11
Pluristem–Dentons: legal services, 202005 supply service Dentons is adivsor with regard to €50m EIB loan financing 2020-05-05
ADC Therapeutics–Deerfield: credit, 202005– convertible credit facility $115m in two conditionable disbursements of $65m + $50m 2020-05-01
Moderna–Lonza: biologics contract manufacturing, 202005–203004 collab strategic 10y manufacture of mRNA1273 vaccine + other Moderna products 2020-05-01
Pfizer–Valneva: Lyme disese vaccine, 202004– collab developm of VLA15 + commerc by Pfizer $130m upfront + $178m milestones + 2-digit tiered royalties 2020-04-30
Kurma–EU (govt): investment, 202004 final closing of Kurma Biofund III totalling €160m incl investor EIF 2020-04-29
Kurma–Institut Pasteur: investment, 202004 final closing of Kurma Biofund III totalling €160m incl investor Pasteur Institute 2020-04-29
Kurma–North Rhine-Westphalia (govt): investment, 202004 final closing of Kurma Biofund III totalling €160m incl investor NRW.BANK 2020-04-29
Kurma–SEVERAL: investment, 202004 final closing of Kurma Biofund III with €160m 2020-04-29
Genedata–Cergentis: genomic software tools, –202004 collab developm of Genedata Selector s/w for automating TLA data analysis workflow 2020-04-28
Gustave Roussy–Biognosys: MS-based proteomics, 202004– collab using proteomic profiling in attempt to repurpose tocilizumab for Covid-19 2020-04-28
Compass Pathways–Atai Life Sciences: investment, 202004 financing round Series B totalling $80m incl existing investor Atai Life Sciences 2020-04-27
Compass Pathways–SEVERAL: investment, 202004 financing round Series B $80m from existing + new investors 2020-04-27
Heidelberg Pharma–Hopp Group: investment, 202004 private placement totalling €14.4m incl €13.7m from main investor Dievini Hopp 2020-04-27
Heidelberg Pharma–OTHER: investment, 202004 private placement totalling €14.4m incl €719k to institutional investors 2020-04-27
Heidelberg Pharma–SEVERAL: investment, 202004 private placement €14.4m with 2.82m new shares at €5.1/share incl €13.7m from Dievini Hopp 2020-04-27
ADC Therapeutics–SEVERAL: investment, 202004–202005 IPO at NYSE $267.6m with 14.1m shares at $19/share 2020-04-24
Pluristem–EU (govt): credit, 202004– EIB financing up to €50m in three milestone-dependent tranches 2020-04-24
Biotecon–EW Group: investment, 202004 acquisition of Biotecon Diagnostics GmbH by BioChek BV 2020-04-23
Noscendo–Earlybird: investment, 202004 financing round Series A incl new investor Earlybird 2020-04-23
Noscendo–HIgh-Tech Gründerfonds: investment, 202004 financing round Series A incl existing investor HTGF 2020-04-23
Noscendo–JIH Family Office: investment, 202004 financing round Series A incl new investor JIH Family Office 2020-04-23
Noscendo–Paua Ventures: investment, 202004 financing round Series A incl new investor Paua Ventures 2020-04-23
Noscendo–SEVERAL: investment, 202004 financing round Series A with existing + new investors 2020-04-23
Noscendo–Wieland Capital: investment, 202004 financing round Series A incl existing investor Wieland Capital 2020-04-23
FoRx Therapeutics–Life Sciences Partners: investment, 202004 seed financing round totalling €10m incl co-investor LSP 2020-04-22
FoRx Therapeutics–Merck (DE): investment, 202004 seed financing round totalling €10m incl co-lead investor M Ventures 2020-04-22
FoRx Therapeutics–Novartis: investment, 202004 seed financing round totalling €10m incl co-lead investor Novartis Venture Fund 2020-04-22
FoRx Therapeutics–Omega Funds: investment, 202004 seed financing round totalling €10m incl co-lead investor Omega Funds 2020-04-22
FoRx Therapeutics–Optimum Strategic Communications: public relations, 202004 service existent by Optimum 2020-04-22
FoRx Therapeutics–Pfizer: investment, 202004 seed financing round totalling €10m incl co-investor Pfizer Ventures 2020-04-22
FoRx Therapeutics–SEVERAL: investment, 202004 seed financing round €10m co-led by M Ventures + Novartis Venture Fund + Omega Funds 2020-04-22
Valneva–Dynavax: SARS-CoV-2 vaccine, 202004– collab development combining Valneva’s vaccine technology with adjuvant CpG 1018 of Dynavax 2020-04-22
Lunaphore–Swiss Entrepreneurs Foundation: investment, 202004 additional CHF2m Series C2 financing from Swiss Entrerpreneurs Fund 2020-04-21
Centogene–Ubirch: blockchain technology, 202004 collab announcing secure blockchain solution for storing SARS-CoV-2 test results 2020-04-17
Evotec–Leon-Nanodrugs: nanoparticle technology, 202004– collab €na strategic partnership incl equity investment 2020-04-16
Evox Therapeutics–Cevec: cell line technology, 202004– license €na for use of CAP technology to produce exosome therapeutics as part of ongoing collab 2020-04-16
Leon-Nanodrugs–Albany Private Equity: investment, 202004 financing round Series B incl existing + co-investor Albany Private Equity Holidngs Pty Ltd 2020-04-16
Leon-Nanodrugs–Bavaria (govt): investment, 202004 financing round Series B incl new + co-investor BayBG 2020-04-16
Leon-Nanodrugs–CD-Venture: investment, 202004 financing round Series B incl existing + co-investor CD-Venture GmbH 2020-04-16
Leon-Nanodrugs–Eckenstein-Geigy-Stiftung: investment, 202004 financing round Series B incl existing + co-investor Eckenstein-Geigy-Stiftung 2020-04-16
Leon-Nanodrugs–Evotec: investment, 202004 financing round Series B incl new + lead investor Evotec 2020-04-16
Leon-Nanodrugs–LOF Leon Partnership: investment, 202004 financing round Series B incl existing + co-investor LOF Leon Partnership LP 2020-04-16
Leon-Nanodrugs–SEVERAL: investment, 202004 financing round Series B led by new investor Evotec 2020-04-16
Leon-Nanodrugs–TVM: investment, 202004 financing round Series B incl existing + co-investor TVM Life Science Innovation I LP 2020-04-16
Centogene–FTI Consulting: public relations, 202004 service existent by FTI Consulting 2020-04-15
MOMA Therapeutics–Nextech: investment, 202004 financing round Series A totalling $86m incl co-investor Nextech Invest 2020-04-15
MOMA Therapeutics–SEVERAL: investment, 202004 financing round Series A $86m led by Third Rock Ventures 2020-04-15
Boehringer–Insilico Medicine: drug target discovery, 202004– collab research using machine learning + Pandomics Discovery Platform 2020-04-14
Roche–Arrakis Therapeutics: RNA-targeting drugs, 202004– collab strategic + license $190m upfront discovery of RNA-targeting small molecule drugs 2020-04-08
Takeda–Evotec: drug discovery services, 202004– collab multi-year €na gene therapy research alliance 2020-04-06
Evotec–PanCella: iPSC technology, 202004– license €na for use of iACT Stealth Cells + FailSafe technology with EVOcells platform 2020-04-02
PanCella–Evotec: investment, 202004 minority equity investment €na by Evotec in connection with license agreement 2020-04-02
Rgenta Therapeutics–Boehringer: investment, 202004 seed financing round totalling $20m incl co-lead investor BIVF 2020-04-02
Rgenta Therapeutics–SEVERAL: investment, 202004 seed financing round $20m co-led by BIVF + Matrix Partners China 2020-04-02
iTeos Therapeutics–SEVERAL: investment, 202004 financing round Series B2 $125m co-led by RA Capital Management + Boxer Capital 2020-04-01
Vaderis Therapeutics–Almac: allosteric AKT inhibitors, 202004 acquisition portfolio of allosteric AKT inhibitors from Almac Discovery Ltd by Vedaris 2020-04-01
Valanx Biotech–IST Cube: investment, 202004c seed financing round totalling €6-digit including investor IST Cube 2020-04-01
Valanx Biotech–Niederösterreich (govt): investment, 202004c seed financing round totalling €6-digit including investor Tecnet Equity 2020-04-01
Valanx Biotech–SEVERAL: investment, 202004c seed financing round €6-digit from IST Cube + Tecnet Equity + SOSV 2020-04-01
Valanx Biotech–SOSV: investment, 202004c seed financing round totalling €6-digit including investor SOSV (US) 2020-04-01
Affinia Therapeutics–Lonza: AAV technology, 202003 license existent from Lonza + Massachusetts Eye and Ear 2020-03-31
Affinia Therapeutics–Lonza: investment, 202003 financing round Series A totalling $60m incl existing + co-investor Lonza 2020-03-31
Affinia Therapeutics–SEVERAL: investment, 202003 financing round Series A $60m co-led by Atlas Venture + F-Prime Capital + NEA 2020-03-31
Gilde Investment–Germany (govt): investment, 202003 first + final close of Gilde Healthcare V fund totalling €416m incl investor KfW Capital 2020-03-31
Gilde Investment–Haniel: investment, 202003 first + final close of Gilde Healthcare V fund totalling €416m incl investor Haniel 2020-03-31
Gilde Investment–SEVERAL: investment, 202003 first + final close of €416m Gilde Healthcare V fund incl investors Philips + Rabo Corp Investments 2020-03-31
Obi Medical–Roche: investment, 202003 acquisition of Obi Medical ApS by Roche 2020-03-31
Provirex–Hamburg (govt): investment, 202003 seed financing from Ascenion + Innovationsstarter Fonds Hamburg 2020-03-31
Provirex–Life Science-Stiftung: investment, 202003 seed financing from Ascenion + Innovationsstarter Fonds Hamburg 2020-03-31
SutroVax–Roche: investment, 202003 financing round Series D totalling $110m incl existing + co-investor Roche Venture Fund 2020-03-26
SutroVax–SEVERAL: investment, 202003 financing round Series D $110m co-led by new investors RA Capital + Janus Henderson 2020-03-26
Debiopharm–3B Pharmaceuticals: radiopharmaceutical, 202003– collab research + license ww excl for radioligand programme targeting CAIX enzyme 2020-03-25
Roche–Forge Therapeutics: antibiotics, 202003– collab research + license option up to $190.5m for FG-LpxC LUNG program for lung infections 2020-03-25
Immunogenesis–Minapharm: biopharma production, 202003– supply €na cell line + process developm + production of I-O-candidate by ProBiogen AG 2020-03-24
Bayer–Curadev: STING agonists, 202003– collab research + license agreem incl upfront payment + €250m milestones + single-digit royalties 2020-03-23
DeepSee project–Germany (govt): grant, 202003– funding from BMWi (ZIM) + Enterprise Singapore for single cell analysis for cancer drug RnD 2020-03-23
DeepSee project–Proteona: single cell analysis, 202003– collab project partner AI-driven multi-omics single cell analysis for cancer drug RnD 2020-03-23
DeepSee project–Singapore (govt): grant, 202003– funding from Enterprise Singapore + German BMWi for single cell analysis for cancer drug RnD 2020-03-23
DeepSee project–Synovo: single cell analysis, 202003– collab project partner AI-driven multi-omics single cell analysis for cancer drug RnD 2020-03-23
DeepSee project–Univ Tübingen: single cell analysis, 202003– collab NMI project partner AI-driven multi-omics single cell analysis for cancer drug RnD 2020-03-23
Koki Holdings–Eppendorf: investment, 202003– acquisition €na of Koki’s Centrifuge + Processing business by Eppendorf from KKR 2020-03-19
next pagenext page 1 2 3 ... 23 24 25 ... 33 34 35  next pagenext page



Advertisement

Picture EBD Group World of Partnering Opportunities 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture EBD Group World of Partnering Opportunities 650x300px

» top